Group 1 - The stock price of Jinling Pharmaceutical reached 7.28 yuan as of the close on August 22, 2025, with an increase of 0.02 yuan, representing a rise of 0.28% compared to the previous trading day [1] - The trading volume on that day was 171,300 hands, with a total transaction amount of 125 million yuan [1] - Jinling Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical raw materials, and formulations, covering multiple therapeutic areas including cardiovascular, anti-tumor, and digestive systems [1] Group 2 - As of August 20, 2025, the total number of shareholders for Jinling Pharmaceutical was 37,622 [1] - On August 22, the net inflow of main funds was 6.3088 million yuan, with a cumulative net inflow of 18.0238 million yuan over the past five days [1]

资金流向方面，8月12日主力资金净流出51.40万元，近五日主力资金累计净流入72.35万元。 风险提示：股市有风险，投资需谨慎。 截至2025年8月12日收盘，津药药业股价报4.60元，较前一交易日下跌0.65%，成交额0.44亿元。盘中振 幅达4.10%，最高触及4.75元，最低下探至4.56元。 津药药业主要从事化学原料药及制剂的研发、生产和销售，业务涵盖抗感染、心脑血管、激素类等多个 领域。公司属于化学制药板块，产品涉及辅助生殖等医疗领域。 8月12日晚间，津药药业公告称，2025年第三次临时股东大会审议通过了《关于变更经营范围、取消监 事会、修订并办理工商变更的议案》等多项议案。 ...

从资金流向来看，振东制药8月8日主力资金净流出4849.18万元，占流通市值的0.67%。近五个交易日累 计净流出4.93亿元，占流通市值的6.78%。 风险提示：以上内容仅供参考，不构成投资建议。股市有风险，投资需谨慎。 振东制药8月8日报收7.25元，较前一交易日下跌1.76%。盘中最高触及7.51元，最低下探至7.12元，全天 振幅达5.28%。当日成交量为859076手，成交金额6.22亿元，换手率为8.57%。 振东制药属于化学制药行业，公司主要从事中成药、化学原料药及制剂的研发、生产和销售。公司产品 涵盖抗肿瘤、心脑血管、抗感染等多个治疗领域。 ...

Core Viewpoint - Ordos City is focusing on developing the biopharmaceutical industry as a key industrial chain, aiming to create an ideal environment for industry transfer and growth [1][2]. Group 1: Business Environment - Ordos has been ranked first in Inner Mongolia's business environment assessment for five consecutive years, promoting a "warm city" business environment brand [1]. - The city has implemented the "Release, Management, and Service" reform and optimized the business environment 6.0 version, enhancing project approval processes and reducing costs for enterprises [1]. Group 2: Policy Support - Ordos has introduced unprecedented policies in technology and talent, including a new version of the technology and talent policy, to attract innovation and development [1][2]. - The city collaborates with top universities and research institutions to establish high-level scientific innovation platforms, fostering a strong talent pool [1]. Group 3: Financial Empowerment - Ordos has developed venture capital, equity investment, and patient capital, with state-owned enterprises participating in the establishment of 13 funds totaling 30.8 billion yuan to support industrial projects [2]. Group 4: Industry Advantages - The city possesses unique advantages in the biopharmaceutical sector, particularly in chemical raw materials, traditional Chinese medicine, and biopharmaceuticals, with a rich variety of high-quality medicinal materials [2]. - Ordos has over 60,000 acres of traditional Chinese medicine cultivation bases, producing 73,000 tons of high-quality medicinal materials annually, providing abundant natural resources for the biopharmaceutical industry [2]. Group 5: Research and Development - The city is actively promoting the innovation and development of traditional Chinese medicine through policies and collaborations with top research institutions [2]. - Ordos is engaging with leading research institutions and enterprises to advance cutting-edge biotechnologies, including synthetic biology and gene editing, accelerating clinical research applications of new technologies [2].